Affinity DataIC50: 0.230nMT: 2°CAssay Description:The activity of the PAR4 antagonists of the present invention were tested in PAR4 expressing cells by monitoring H-Ala-Phe(4-F)-Pro-Gly-Trp-Leu-Val-L...More data for this Ligand-Target Pair
Affinity DataIC50: 0.230nMT: 2°CAssay Description:The activity of the PAR4 antagonists of the present invention were tested in PAR4 expressing cells by monitoring H-Ala-Phe(4-F)-Pro-Gly-Trp-Leu-Val-L...More data for this Ligand-Target Pair
Affinity DataIC50: 0.290nMT: 2°CAssay Description:The activity of the PAR4 antagonists of the present invention were tested in PAR4 expressing cells by monitoring H-Ala-Phe(4-F)-Pro-Gly-Trp-Leu-Val-L...More data for this Ligand-Target Pair
Affinity DataIC50: 0.310nMT: 2°CAssay Description:The activity of the PAR4 antagonists of the present invention were tested in PAR4 expressing cells by monitoring H-Ala-Phe(4-F)-Pro-Gly-Trp-Leu-Val-L...More data for this Ligand-Target Pair
Affinity DataIC50: 0.320nMAssay Description:The FLIPR assay is an exemplary in vitro assay for measuring the activity of the PAR4 antagonists of the present invention. In this assay, intracellu...More data for this Ligand-Target Pair
Affinity DataIC50: 0.350nMT: 2°CAssay Description:The activity of the PAR4 antagonists of the present invention were tested in PAR4 expressing cells by monitoring H-Ala-Phe(4-F)-Pro-Gly-Trp-Leu-Val-L...More data for this Ligand-Target Pair
Affinity DataIC50: 0.360nMT: 2°CAssay Description:The activity of the PAR4 antagonists of the present invention were tested in PAR4 expressing cells by monitoring H-Ala-Phe(4-F)-Pro-Gly-Trp-Leu-Val-L...More data for this Ligand-Target Pair
Affinity DataIC50: 0.360nMT: 2°CAssay Description:The activity of the PAR4 antagonists of the present invention were tested in PAR4 expressing cells by monitoring H-Ala-Phe(4-F)-Pro-Gly-Trp-Leu-Val-L...More data for this Ligand-Target Pair
Affinity DataIC50: 0.360nMT: 2°CAssay Description:The activity of the PAR4 antagonists of the present invention were tested in PAR4 expressing cells by monitoring H-Ala-Phe(4-F)-Pro-Gly-Trp-Leu-Val-L...More data for this Ligand-Target Pair
Affinity DataIC50: 0.380nMT: 2°CAssay Description:The activity of the PAR4 antagonists of the present invention were tested in PAR4 expressing cells by monitoring H-Ala-Phe(4-F)-Pro-Gly-Trp-Leu-Val-L...More data for this Ligand-Target Pair
Affinity DataIC50: 0.390nMT: 2°CAssay Description:The activity of the PAR4 antagonists of the present invention were tested in PAR4 expressing cells by monitoring H-Ala-Phe(4-F)-Pro-Gly-Trp-Leu-Val-L...More data for this Ligand-Target Pair
Affinity DataIC50: 0.410nMT: 2°CAssay Description:The activity of the PAR4 antagonists of the present invention were tested in PAR4 expressing cells by monitoring H-Ala-Phe(4-F)-Pro-Gly-Trp-Leu-Val-L...More data for this Ligand-Target Pair
Affinity DataIC50: 0.450nMT: 2°CAssay Description:The activity of the PAR4 antagonists of the present invention were tested in PAR4 expressing cells by monitoring H-Ala-Phe(4-F)-Pro-Gly-Trp-Leu-Val-L...More data for this Ligand-Target Pair
Affinity DataIC50: 0.470nMT: 2°CAssay Description:The activity of the PAR4 antagonists of the present invention were tested in PAR4 expressing cells by monitoring H-Ala-Phe(4-F)-Pro-Gly-Trp-Leu-Val-L...More data for this Ligand-Target Pair
Affinity DataIC50: 0.480nMT: 2°CAssay Description:The activity of the PAR4 antagonists of the present invention were tested in PAR4 expressing cells by monitoring H-Ala-Phe(4-F)-Pro-Gly-Trp-Leu-Val-L...More data for this Ligand-Target Pair
Affinity DataIC50: 0.490nMT: 2°CAssay Description:The activity of the PAR4 antagonists of the present invention were tested in PAR4 expressing cells by monitoring H-Ala-Phe(4-F)-Pro-Gly-Trp-Leu-Val-L...More data for this Ligand-Target Pair
Affinity DataIC50: 0.5nMT: 2°CAssay Description:The activity of the PAR4 antagonists of the present invention were tested in PAR4 expressing cells by monitoring H-Ala-Phe(4-F)-Pro-Gly-Trp-Leu-Val-L...More data for this Ligand-Target Pair
Affinity DataIC50: 0.530nMT: 2°CAssay Description:The activity of the PAR4 antagonists of the present invention were tested in PAR4 expressing cells by monitoring H-Ala-Phe(4-F)-Pro-Gly-Trp-Leu-Val-L...More data for this Ligand-Target Pair
Affinity DataIC50: 0.560nMT: 2°CAssay Description:The activity of the PAR4 antagonists of the present invention were tested in PAR4 expressing cells by monitoring H-Ala-Phe(4-F)-Pro-Gly-Trp-Leu-Val-L...More data for this Ligand-Target Pair
Affinity DataIC50: 0.560nMT: 2°CAssay Description:The activity of the PAR4 antagonists of the present invention were tested in PAR4 expressing cells by monitoring H-Ala-Phe(4-F)-Pro-Gly-Trp-Leu-Val-L...More data for this Ligand-Target Pair
Affinity DataIC50: 0.570nMT: 2°CAssay Description:The activity of the PAR4 antagonists of the present invention were tested in PAR4 expressing cells by monitoring H-Ala-Phe(4-F)-Pro-Gly-Trp-Leu-Val-L...More data for this Ligand-Target Pair
Affinity DataIC50: 0.570nMT: 2°CAssay Description:The activity of the PAR4 antagonists of the present invention were tested in PAR4 expressing cells by monitoring H-Ala-Phe(4-F)-Pro-Gly-Trp-Leu-Val-L...More data for this Ligand-Target Pair
Affinity DataIC50: 0.590nMAssay Description:The FLIPR assay is an exemplary in vitro assay for measuring the activity of the PAR4 antagonists of the present invention. In this assay, intracellu...More data for this Ligand-Target Pair
Affinity DataIC50: 0.600nMT: 2°CAssay Description:The activity of the PAR4 antagonists of the present invention were tested in PAR4 expressing cells by monitoring H-Ala-Phe(4-F)-Pro-Gly-Trp-Leu-Val-L...More data for this Ligand-Target Pair
Affinity DataIC50: 0.670nMT: 2°CAssay Description:The activity of the PAR4 antagonists of the present invention were tested in PAR4 expressing cells by monitoring H-Ala-Phe(4-F)-Pro-Gly-Trp-Leu-Val-L...More data for this Ligand-Target Pair
Affinity DataIC50: 0.680nMT: 2°CAssay Description:The activity of the PAR4 antagonists of the present invention were tested in PAR4 expressing cells by monitoring H-Ala-Phe(4-F)-Pro-Gly-Trp-Leu-Val-L...More data for this Ligand-Target Pair
Affinity DataIC50: 0.690nMT: 2°CAssay Description:The activity of the PAR4 antagonists of the present invention were tested in PAR4 expressing cells by monitoring H-Ala-Phe(4-F)-Pro-Gly-Trp-Leu-Val-L...More data for this Ligand-Target Pair
Affinity DataIC50: 0.690nMT: 2°CAssay Description:The activity of the PAR4 antagonists of the present invention were tested in PAR4 expressing cells by monitoring H-Ala-Phe(4-F)-Pro-Gly-Trp-Leu-Val-L...More data for this Ligand-Target Pair
Affinity DataIC50: 0.690nMT: 2°CAssay Description:The activity of the PAR4 antagonists of the present invention were tested in PAR4 expressing cells by monitoring H-Ala-Phe(4-F)-Pro-Gly-Trp-Leu-Val-L...More data for this Ligand-Target Pair
Affinity DataIC50: 0.710nMT: 2°CAssay Description:The activity of the PAR4 antagonists of the present invention were tested in PAR4 expressing cells by monitoring H-Ala-Phe(4-F)-Pro-Gly-Trp-Leu-Val-L...More data for this Ligand-Target Pair
Affinity DataIC50: 0.720nMT: 2°CAssay Description:The activity of the PAR4 antagonists of the present invention were tested in PAR4 expressing cells by monitoring H-Ala-Phe(4-F)-Pro-Gly-Trp-Leu-Val-L...More data for this Ligand-Target Pair
Affinity DataIC50: 0.720nMT: 2°CAssay Description:The activity of the PAR4 antagonists of the present invention were tested in PAR4 expressing cells by monitoring H-Ala-Phe(4-F)-Pro-Gly-Trp-Leu-Val-L...More data for this Ligand-Target Pair
Affinity DataIC50: 0.720nMAssay Description:The FLIPR assay is an exemplary in vitro assay for measuring the activity of the PAR4 antagonists of the present invention. In this assay, intracellu...More data for this Ligand-Target Pair
Affinity DataIC50: 0.730nMAssay Description:The FLIPR assay is an exemplary in vitro assay for measuring the activity of the PAR4 antagonists of the present invention. In this assay, intracellu...More data for this Ligand-Target Pair
Affinity DataIC50: 0.740nMT: 2°CAssay Description:The activity of the PAR4 antagonists of the present invention were tested in PAR4 expressing cells by monitoring H-Ala-Phe(4-F)-Pro-Gly-Trp-Leu-Val-L...More data for this Ligand-Target Pair
Affinity DataIC50: 0.760nMT: 2°CAssay Description:The activity of the PAR4 antagonists of the present invention were tested in PAR4 expressing cells by monitoring H-Ala-Phe(4-F)-Pro-Gly-Trp-Leu-Val-L...More data for this Ligand-Target Pair
Affinity DataIC50: 0.760nMAssay Description:The FLIPR assay is an exemplary in vitro assay for measuring the activity of the PAR4 antagonists of the present invention. In this assay, intracellu...More data for this Ligand-Target Pair
Affinity DataIC50: 0.790nMT: 2°CAssay Description:The activity of the PAR4 antagonists of the present invention were tested in PAR4 expressing cells by monitoring H-Ala-Phe(4-F)-Pro-Gly-Trp-Leu-Val-L...More data for this Ligand-Target Pair
Affinity DataIC50: 0.810nMAssay Description:Antagonist activity at full-length human PAR4 expressed in HEK293 cells assessed as inhibition of AYPGKF-induced intracellular calcium mobilization p...More data for this Ligand-Target Pair
Affinity DataIC50: 0.840nMT: 2°CAssay Description:The activity of the PAR4 antagonists of the present invention were tested in PAR4 expressing cells by monitoring H-Ala-Phe(4-F)-Pro-Gly-Trp-Leu-Val-L...More data for this Ligand-Target Pair
Affinity DataIC50: 0.850nMT: 2°CAssay Description:The activity of the PAR4 antagonists of the present invention were tested in PAR4 expressing cells by monitoring H-Ala-Phe(4-F)-Pro-Gly-Trp-Leu-Val-L...More data for this Ligand-Target Pair
Affinity DataIC50: 0.860nMAssay Description:The FLIPR assay is an exemplary in vitro assay for measuring the activity of the PAR4 antagonists of the present invention. In this assay, intracellu...More data for this Ligand-Target Pair
Affinity DataIC50: 0.870nMAssay Description:The FLIPR assay is an exemplary in vitro assay for measuring the activity of the PAR4 antagonists of the present invention. In this assay, intracellu...More data for this Ligand-Target Pair
Affinity DataIC50: 0.890nMAssay Description:Antagonist activity at full-length human PAR4 expressed in HEK293 cells assessed as inhibition of AYPGKF-induced intracellular calcium mobilization p...More data for this Ligand-Target Pair
Affinity DataIC50: 0.920nMT: 2°CAssay Description:The activity of the PAR4 antagonists of the present invention were tested in PAR4 expressing cells by monitoring H-Ala-Phe(4-F)-Pro-Gly-Trp-Leu-Val-L...More data for this Ligand-Target Pair
Affinity DataIC50: 0.940nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Affinity DataIC50: 0.950nMT: 2°CAssay Description:The activity of the PAR4 antagonists of the present invention were tested in PAR4 expressing cells by monitoring H-Ala-Phe(4-F)-Pro-Gly-Trp-Leu-Val-L...More data for this Ligand-Target Pair
Affinity DataIC50: 0.960nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Affinity DataIC50: 0.970nMAssay Description:The FLIPR assay is an exemplary in vitro assay for measuring the activity of the PAR4 antagonists of the present invention. In this assay, intracellu...More data for this Ligand-Target Pair
Affinity DataIC50: 0.980nMAssay Description:Antagonist activity at full-length human PAR4 expressed in HEK293 cells assessed as inhibition of AYPGKF-induced intracellular calcium mobilization p...More data for this Ligand-Target Pair